Skip to content
Open in App
Chugai Pharma logo

Chugai Pharma

web2

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, devel...

Symbol · 4519
Company profile

About

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Chugai Pharmaceutical Co., Ltd. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

ACHIEVE 3 Phase III full results reported for orforglipron

KEY STEP

On February 26, 2026, Chugai announced positive full results from Lilly’s Phase III ACHIEVE 3 study of orforglipron in type 2 diabetes. Orforglipron was discovered by Chugai and is licensed to Lilly for worldwide development and commercialization.

Roadmap reference

Foundayo receives United States FDA approval for obesity

KEY STEP

On April 1, 2026, the United States FDA approved Foundayo, orforglipron, for adults with obesity or overweight with weight related medical problems. The molecule was discovered by Chugai and is exclusively licensed to Eli Lilly for global development and commercialization.

Roadmap reference

Chugai begins recognizing Foundayo royalty income

KEY STEP

On July 24, 2026, Chugai reported that it had started recognizing royalty income from Foundayo in the second quarter following the product's United States launch in April. Lilly later reported $98 million of Foundayo sales for Q2 2026.

Roadmap reference
People

Company team

AS

Andre S. Hoffmann

Member of the International Advisory Council

Company leadership profile.

SK

Sonosuke Kadonaga

Member of the International Advisory Council

Company leadership profile.

OO

Osamu Okuda

President, CEO & Chairman

Company leadership profile.

ON

Osamu Nagayama

Honorary Chairman & Senior Advisor

Company leadership profile.

IT

Iwaaki Taniguchi

Senior Executive Officer, CFO, Head of Finance & Director

Company leadership profile.

HI

Hitoshi Iikura

Executive VP, Head of Corporate Planning Dept. & Director

Company leadership profile.

HL

Henry L. Nordhoff

Chairman of the International Advisory Council

Company leadership profile.

FT

Fumio Tateishi

Outside Independent Director

Company leadership profile.

TA

Teresa A. Graham

Non-Executive Director

Company leadership profile.

FB

Franz Bernhard Humer

Member of the International Advisory Council

Company leadership profile.

VH

Victor Halberstadt

Member of the International Advisory Council

Company leadership profile.

WM

William M. Burns

Member of the International Advisory Council

Company leadership profile.

AJ

Arnold J. Levine

Member of the International Advisory Council

Company leadership profile.

AC

Andrew C. von Eschenbach

Member of the International Advisory Council

Company leadership profile.

VH

Virginia Hilda Brunette Maxwell Bottomley

Member of the International Advisory Council

Company leadership profile.

HT

Hideo Teramoto

Independent Outside Director

Company leadership profile.

TS

Thomas Schinecker

Director

Company leadership profile.

BL

Boris L. Zaitra

Director

Company leadership profile.

KM

Kinuko Mitani

Independent Outside Director

Company leadership profile.

SY

Shigehiro Yamada

Full-time Audit & Supervisory Board Member

Company leadership profile.

KM

Kenichi Masuda

Outside Independent Audit & Supervisory Board Member

Company leadership profile.

MH

Masayoshi Higuchi

Full-time Audit & Supervisory Board Member

Company leadership profile.

YW

Yumiko Waseda

Outside Independent Audit & Supervisory Board Member

Company leadership profile.

MY

Mami Yunoki

Outside Independent Audit & Supervisory Board Member

Company leadership profile.

Expert coverage

2 experts evaluated Chugai Pharma.

Orbitrum research

Experts evaluating Chugai Pharma

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment